Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma
Phase of Trial: Phase II
Latest Information Update: 26 May 2016
At a glance
- Drugs Ofatumumab (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Biomarker; Pharmacodynamics
- 21 Jul 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2012-001597-29).
- 21 Jul 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.
- 26 Apr 2012 New trial record